Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 6

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 6
---
 particular, as we are a China-based company incorporated in the Cayman Islands, you should pay special attention to subsections headed“ Item 3. Key Information-3. D. Risk Factors-Other Risks and Risks Related to Doing Business in China. ”

The following summarizes some, but not all, of the risks provided below. Please carefully consider all of the information discussed in this Item 3. D. “Risk Factors” in this annual report for a more thorough description of these and other risks.

Risks Relating to Our Financial Position and Need for Capital

  Risks relating to our need for additional funding  

  Risks relating to our existing and future indebtedness  

Table of Contents

Risks Relating to Our Oncology/Immunology Operations and Development of Our Drug Candidates

  Risks relating to our approach to the discovery and development of drug candidates and the lengthy, expensive and uncertain clinical development process  

  Risks relating to expediting regulatory review, obtaining and maintaining regulatory approval and ongoing regulatory review for our drug candidates  

  Risks relating to the commercialization of our drug candidates  

  Risks relating to undesirable side effects of our drug candidates  

  Risks relating to competition in discovering, developing and commercializing drugs  

  Risks relating to our collaboration partners with respect to clinical trials, marketing and distribution  

  Risks relating to our international operations  

Risks Relating to Sales of Our Internally Developed Drugs and Other Drugs

  Risks relating to obtaining and maintaining permits and licenses for our and our joint ventures ’ pharmaceutical operations in China  

  Risks relating to leveraging our Other Ventures ’ prescription drug business to commercialize our internally developed drug candidates  

  Risks relating to competition in selling our approved, internally developed drugs and drugs of our Other Ventures  

  Risks relating to maintaining and enhancing the brand recognition of our drugs  

  Risks relating to the availability of reimbursement of our drugs, the lack of which could diminish our sales or profitability  

  Risks relating to counterfeit products in China  

  Risks relating to rapid changes in the pharmaceutical industry rendering our products obsolete  
 ──────────────────────────────────────────────────────────────────────────────────────────────────

  Risks relating to cultivating or sourcing raw materials  

  Risks relating to adverse publicity of us, our collaboration partners, our joint ventures or our products  

Risks Relating to Our Dependence on Third Parties

  Risks relating to disagreements with current or future collaboration partners which we rely on for certain drug development activities including the